Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00813618 · ClinicalTrials.gov registry record · Phase 1
Study of MEDI 507 in the Treatment of Pediatric Patients
A Phase 1 study of Graft-Versus-Host Disease, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 6
- Study locations
NCT00813618 is a Phase 1 study of Graft-Versus-Host Disease that has completed, run by MedImmune. The registered enrollment target is 10 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT00813618, a Phase 1 study of Graft-Versus-Host Disease, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 6
- Study locations
Study Summary
To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.
Conditions Studied
Interventions
- DRUG MEDI-507
Study Locations (6)
Alabama
- Children's Hospital - Birmingham
California
- Children's Hospital of Orange County - Orange
Illinois
- Children's Memorial Hospital - Chicago
Michigan
- Univ. of Michigan Medical Center - Ann Arbor
New Jersey
- Hackensack U. Medical Center - Hackensack
Pennsylvania
- The Children's Hosp. of Phila., Abramson Ped. Research Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1999-09 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00813618
The ClinicalTrials.gov registry entry for NCT00813618 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (88% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 1 intervention - of which MEDI-507 is the first listed.
NCT00813618 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00813618 about?
NCT00813618 is a clinical study titled "Study of MEDI 507 in the Treatment of Pediatric Patients". To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.
What is the current status of trial NCT00813618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 1999-09. Estimated completion is 2004-08.
What conditions does trial NCT00813618 study?
This clinical trial studies the following conditions: Graft-Versus-Host Disease.
What interventions are being tested in trial NCT00813618?
The interventions under investigation include: MEDI-507 (DRUG).
Who is sponsoring clinical trial NCT00813618?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00813618 being conducted?
This trial has 6 study locations across Alabama, California, Illinois, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-Versus-Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 1
-
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
-
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Optimizing PTCy Dose and Timing
ACTIVE NOT RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.